SK-RC-20 is a primary renal cancer cell line with a doubling time of 55 hours.
This cell line is from a collection of renal cell carcinoma (RCC) cell lines derived from the primary tumors of patients who underwent surgery.
This cell line was established from a 46-year-old male of unknown ethnicity with renal cell carcinoma.
All cell lines were established in Dr. Lloyd Old’s laboratory, from patients undergoing nephrectomy at Memorial Hospital, MSK, between the years 1972 and 1987. Fresh surgical specimens were obtained from Tumor Procurement Services, Department of Surgical Pathology, Memorial Hospital, MSK.
Lloyd J. Old, MD, former William E. Snee Chair in Cancer Immunology, MSK; former Director, New York Branch, Ludwig Institute for Cancer Research, and members of the Old Laboratory
- Cowley G et al. (2014) Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Scientific data, 1, 140035. (PubMed ID: 25984343)
- Ghandi M et al. (2019) Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature, 569(7757), 503-508. (PubMed: 31068700)
- Express License: For internal research purposes by a for-profit entity: Utilize MSK’s Express License, see here for fillable PDF. In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. Please note: This license is only available for select cell lines, including this one. To proceed, please fill in all relevant fields and send it [email protected]. Once this license has been executed by MSK, you will receive a signed copy and payment instructions; all payments up to $10,000 must be made by credit card.
- Commercial License: Contact MSK’s Tangible Research Materials team at [email protected].
- For non-licensing requests from academic-research institutions: Contact MSK’s Antibody & Bioresource Core Facility at [email protected].
- RRID: CVCL_V605